A recent study has shown that intraperitoneal injections of anti‐human epidermal growth factor receptor (EGFR) antibody‐modified LNPs achieved up to 80% gene editing in ovarian tumor mouse models, leading to suppressed tumor growth and extended survival rates [160]. This evidence concerns the gene EGFR and ovarian neoplasm.